| 1 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 8,794 |
| 2 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,121 |
| 3 | Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches | Journal of Extracellular Vesicles | 2024 | 3,550 |
| 4 | STATs in cancer inflammation and immunity: a leading role for STAT3 | Nature Reviews Cancer | 2009 | 3,383 |
| 5 | Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots | Lipids | 1970 | 3,017 |
| 6 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 2,656 |
| 7 | Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation | Nature Cell Biology | 2018 | 2,409 |
| 8 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Lancet, The | 2008 | 2,179 |
| 9 | Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 | Autophagy | 2021 | 2,168 |
| 10 | Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | 2011 | 2,138 |
| 11 | A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes | Nature | 1992 | 1,986 |
| 12 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study | Lancet, The | 2020 | 1,952 |
| 13 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | Lancet Oncology, The | 2020 | 1,928 |
| 14 | The human tumor microbiome is composed of tumor type–specific intracellular bacteria | Science | 2020 | 1,917 |
| 15 | Association of reactive oxygen species levels and radioresistance in cancer stem cells | Nature | 2009 | 1,883 |
| 16 | Macrophages in immunoregulation and therapeutics | Signal Transduction and Targeted Therapy | 2023 | 1,871 |
| 17 | Aptamers as targeted therapeutics: current potential and challenges | Nature Reviews Drug Discovery | 2016 | 1,817 |
| 18 | Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles | Nature | 2010 | 1,812 |
| 19 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update | Journal of Clinical Oncology | 2021 | 1,806 |
| 20 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 1,799 |
| 21 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature | 2019 | 1,726 |
| 22 | Binding of soluble form of fibroblast surface protein, fibronectin, to collagen | International Journal of Cancer | 1977 | 1,708 |
| 23 | Revisiting STAT3 signalling in cancer: new and unexpected biological functions | Nature Reviews Cancer | 2014 | 1,669 |
| 24 | Quantitative analysis of phospholipids by thin‐layer chromatography and phosphorus analysis of spots | Lipids | 1966 | 1,474 |
| 25 | Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data | Lancet Oncology, The | 2010 | 1,458 |
| 26 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study | Lancet, The | 2021 | 1,398 |
| 27 | Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment | Nature Reviews Immunology | 2007 | 1,369 |
| 28 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia | Blood | 2019 | 1,346 |
| 29 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials | Lancet Oncology, The | 2020 | 1,334 |
| 30 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | Journal of Hepatology | 2022 | 1,293 |
| 31 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,275 |
| 32 | Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR | Molecular Cell | 1999 | 1,269 |
| 33 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Lancet, The | 2010 | 1,254 |
| 34 | 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks | Cell | 2010 | 1,253 |
| 35 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Lancet, The | 2010 | 1,240 |
| 36 | Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study | Blood | 2000 | 1,190 |
| 37 | Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis | Cancer Cell | 2014 | 1,182 |
| 38 | The current state and future directions of RNAi-based therapeutics | Nature Reviews Drug Discovery | 2019 | 1,162 |
| 39 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia | Blood | 2017 | 1,160 |
| 40 | Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET) | Clinical Infectious Diseases | 2010 | 1,152 |
| 41 | Oncogenically active MYD88 mutations in human lymphoma | Nature | 2010 | 1,123 |
| 42 | Initial genome sequencing and analysis of multiple myeloma | Nature | 2011 | 1,068 |
| 43 | Induced pluripotent stem cell technology: a decade of progress | Nature Reviews Drug Discovery | 2016 | 1,065 |
| 44 | Association analysis identifies 65 new breast cancer risk loci | Nature | 2017 | 1,044 |
| 45 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers | Cell | 2020 | 1,033 |
| 46 | Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Nature Medicine | 2006 | 1,016 |
| 47 | m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer | Cancer Cell | 2020 | 993 |
| 48 | Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | | 2018 | 986 |
| 49 | m6A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells | Cell Reports | 2017 | 982 |
| 50 | Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | Lancet Oncology, The | 2015 | 977 |
